Associated Papers
Local Ancestry-Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations.
Steiner HE et al.
Clinical Pharmacology and Therapeutics, 2023
Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects.
Altawil Y et al.
Cardiovascular Therapeutics, 2023
Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement.
Li J et al.
Medicine, 2022
The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.
Wanounou M et al.
Clinical Pharmacology and Therapeutics, 2022
Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin.
Xia X et al.
European Journal of Clinical Pharmacology, 2022
The Role of GRP and MGP in the Development of Non-Hemorrhagic VKCFD1 Phenotypes.
Ghosh S et al.
International Journal of Molecular Sciences, 2022
To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study.
Xia X et al.
European Journal of Clinical Pharmacology, 2022
Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.
Muyambo S et al.
Omics : a Journal of Integrative Biology, 2022
Ethnic Diversity and Warfarin Pharmacogenomics.
Asiimwe IG et al.
Frontiers in Pharmacology, 2022
Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
Ndadza A et al.
Journal of Thrombosis and Haemostasis : Jth, 2021
Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients.
Tanaka T et al.
Genes, 2021
A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.
Wang Z et al.
Drug Metabolism and Pharmacokinetics, 2021
A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K et al.
Journal of Clinical Pharmacy and Therapeutics, 2021
Value of VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population.
Harikrishnan S et al.
Indian Heart Journal, 2018
Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
Bryk AH et al.
Vascular Pharmacology, 2018
Association between Vitamin K Epoxide Reductase (VKORC1) -1639G>A Polymorphism and Osteoporosis in Postmenopausal Women.
Kutluturk F et al.
Endocrine, Metabolic & Immune Disorders Drug Targets, 2018
The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement.
Tang XY et al.
Journal of Clinical Pharmacy and Therapeutics, 2017
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.
Ferrari M et al.
European Journal of Clinical Pharmacology, 2017
The VKORC1 polymorphism rs9923231 is associated with aneurysms of the ascending aorta in an Austrian population.
Andreas M et al.
Thrombosis Research, 2017
Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.
Hamadeh IS et al.
Clinical and Translational Science, 2016
VKORC1 and CYP2C9 genotype distribution in Asian countries.
Gaikwad T et al.
Thrombosis Research, 2014
Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
Bazan NS et al.
Irish Journal of Medical Science, 2014
Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.
Zuchinali P et al.
Journal of Thrombosis and Thrombolysis, 2014
A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.
Chen J et al.
Plos One, 2014
Pharmacogenetics of warfarin: challenges and opportunities.
Lee MT et al.
Journal of Human Genetics, 2013
Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.
Kumar DK et al.
Journal of Pharmacology & Pharmacotherapeutics, 2013
Novel associations of VKORC1 variants with higher acenocoumarol requirements.
Anton AI et al.
Plos One, 2013
Association of functional VKORC1 promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population.
Ragia G et al.
Disease Markers, 2013
Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK et al.
Journal of Clinical Pharmacy and Therapeutics, 2012
The pharmacogenetics of the response to warfarin in Chinese.
Lam MP et al.
British Journal of Clinical Pharmacology, 2012
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
Cavallari LH et al.
Pharmacogenetics and Genomics, 2012
Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.
Rathore SS et al.
Plos One, 2012
[Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
Liu Y et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences, 2011
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Johnson JA et al.
Clinical Pharmacology and Therapeutics, 2011
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
Suriapranata IM et al.
Bmc Medical Genetics, 2011
[Possible application of pharmacogenomics to warfarin therapy].
Murata M
Rinsho Byori. the Japanese Journal of Clinical Pathology, 2011
Genetic warfarin dosing: tables versus algorithms.
Finkelman BS et al.
Journal of the American College of Cardiology, 2011
Gamma-glutamyl carboxylase and its influence on warfarin dose.
King CR et al.
Thrombosis and Haemostasis, 2010
New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H et al.
British Journal of Clinical Pharmacology, 2010
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Limdi NA et al.
Blood, 2010
Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis.
Yang L et al.
Thrombosis Research, 2010
[Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].
Stępień E et al.
Kardiologia Polska, 2010
Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
Ohno M et al.
European Journal of Clinical Pharmacology, 2009
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA et al.
Pharmacogenomics, 2009
A multiplex assay for detecting genetic variations in CYP2C9, VKORC1, and GGCX involved in warfarin metabolism.
Rai AJ et al.
Clinical Chemistry, 2009
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Gage BF et al.
Clinical Pharmacology and Therapeutics, 2008
Pharmacogenetics of warfarin: current status and future challenges.
Wadelius M et al.
The Pharmacogenomics Journal, 2007
Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R et al.
Thrombosis Research, 2007
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T et al.
Thrombosis Research, 2007